Skin and Soft Tissue Mucormycosis in Patients Receiving Bruton Tyrosine Kinase Inhibitors: Case Report and Literature Review
Bruton tyrosine kinase inhibitors (BTKis) have been associated with an increased risk of invasive fungal disease, with skin and soft tissue mucormycosis accounting for a minority of cases. We present a 72-year-old patient with chronic lymphocytic leukemia who developed necrotizing fasciitis and myositis due to <i>Lichtheimia</i> spp after 4 months of therapy with the second-generation BTKi zanubrutinib, with a fatal outcome despite aggressive treatment. Our literature review identified 7 additional cases of BTKi-associated skin and soft tissue mucormycosis, revealing an all-cause mortality rate of 37.5%. Two-thirds of the patients had a previous trauma or skin lesion.
Authors
- María Asunción Pérez‐Jacoiste Asín (ORCID: https://orcid.org/0000-0002-0477-2337)
- Mario Fernández‐Ruiz (ORCID: https://orcid.org/0000-0002-0315-8001)
- Isabel Rodríguez‐Góncer (ORCID: https://orcid.org/0000-0003-2150-5748)
- Nieves López‐Muñoz (ORCID: https://orcid.org/0000-0003-0090-6673)
- Jorge Boán (ORCID: https://orcid.org/0000-0003-2682-0819)
- Javier de la Serna (ORCID: https://orcid.org/0000-0003-3904-1101)
- Eduardo Aparicio‐Minguijón (ORCID: https://orcid.org/0009-0007-1497-8770)
- Ana Pérez‐Ayala (ORCID: https://orcid.org/0000-0001-6426-6279)
- Ana B. Enguita
Institutions
- Universidad Complutense de Madrid (ES)
- Instituto de Salud Carlos III (ES)
- Hospital Universitario 12 De Octubre (ES)
- Centro de Investigación Biomédica en Red (ES)
Publication Details
- Journal
- Open Forum Infectious Diseases
- Published
- 2025-11-07
- DOI
- https://doi.org/10.1093/ofid/ofaf691
- Citations
- 1
- Primary Topic
- Chronic Lymphocytic Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 1.63